NCT00882518 - Efficacy and Safety of Quetiapine Fumarate in the Treatment of Schizophrenic Patients | Biotech Hunter

Enrollment

388

Participants

Timeline

Start Date

April 30, 2009

Primary Completion Date

July 31, 2010

Study Completion Date

July 31, 2010

Conditions

Schizophrenia

Interventions

DRUG

Quetiapine Fumarate (SEROQUEL) Extended-Release (XR)

200 mg or 300 mg, oral, single dose

DRUG

Chlorpromazine

50 mg, oral, double dose

Trial Locations (11)

Research Site, Hunan

Research Site, Guangzhou

Research Site, Baoding

Research Site, Harbin

Research Site, Wuhan

Research Site, Changsha

Research Site, Nanjing

Research Site, Xi’an

Research Site, Kunming

Research Site, Beijing

Research Site, Shanghai